IP Library › Granted Patent US 11,466,057
Granted Patent B2
US 11,466,057 · App. 16/916,459 · Granted Oct 11, 2022

Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Inventors: Clara Belzer (Wageningen, NL); Willem Meindert De Vos (Ede, NL); Patrice Daniel Cani (Brussels, BE)
Assignees: WAGENINGEN UNIVERSITEIT; UNIVERSITÉ CATHOLIQUE DE LOUVAIN
C07K14/195A61P3/06A61P3/08C12N1/20A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,466,057
App. No.
16/916,459
Granted
Oct 11, 2022
Kind
B2
Abstract

It has been found that an extracellular polypeptide derived from Akkermansia municiphila is capable of modulating and/or promoting gut mucosal immune system function and/or maintaining and/or restoring metabolic status and/or increasing the physical integrity of the gut mucosal barrier in a mammal. The polypeptide or host cells comprising such polypeptide may be employed to prevent and/or treat a variety of conditions that benefit from an increased physical integrity of the gut mucosal barrier and/or an improved gut mucosal immune system function and metabolic status.

Claims (7)

1. A composition comprising an isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 over the entire length of SEQ ID NO: 1, said polypeptide being capable of effecting immune signaling and/or affecting intestinal barrier function and/or affecting glucose and/or cholesterol and/or triglyceride homeostasis, and a pharmaceutically or alimentary acceptable carrier, wherein the pharmaceutically or alimentary acceptable carrier is formulated for oral delivery and is encapsulated with an enteric coating.

2. The composition according to claim 1 , which is a nutritional composition or a pharmaceutical composition.

3. The composition of claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1.

4. The composition according to claim 1 , wherein the polypeptide retains activity while passing through the stomach.

5. The composition according to claim 4 , wherein the pharmaceutically or alimentary acceptable carrier further comprises one or more controlled release agents.

6. The composition according to claim 4 , wherein the pharmaceutically or alimentary acceptable carrier further comprises a mucosal binding agent.

7. The composition according to claim 1 , wherein the polypeptide comprises between one and ten amino acid substitutions relative to SEQ ID NO:1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2025
From: ADVANCED MICROBIOME INTERVENTIONS B.V.
To: COMPAGNIE GERVAIS DANONE
Reel/Frame 071836/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2024
From: WAGENINGEN UNIVERSITEIT; UNIVERSITÉ CATHOLIQUE DE LOUVAIN
To: ADVANCED MICROBIOME INTERVENTIONS B.V.
Reel/Frame 069285/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2022
From: BELZER, CLARA; DE VOS, WILLEM MEINDERT; CANI, PATRICE DANIEL
To: WAGENINGEN UNIVERSITEIT; UNIVERSITÉ CATHOLIQUE DE LOUVAIN
Reel/Frame 060880/0831 →
Priority Claims (1)
EP 15166598 · May 6, 2015 · regional
Continuity (2)
Continuation 15571175
Related Publication 20210147489A1 · May 20, 2021
Cited By (1)
US 12,642,821